Role of the leukocyte-rich PRP components in tissue repair and regeneration
Keywords:
LR-PRP, platelet concentration, luekocytes, mononuclear cells, neutrophils, erythrocytesAbstract
Background: Platelet-rich plasma (PRP) is an autologous plasma derivative, widely used in regenerative medicine, and recently applied to aesthetic medicine. In the literature, many types of PRP are described, and the presence and amount of leukocytes are the subject of discussion, particularly for the so-called leukocyte-rich PRP (LR-PRP).
Aim: This narrative review aims to analyse the different compositions of LR-PRP to highlight how their characterization can affect the results of product application.
Methods: A literature search was conducted in the PubMed database for relevant studies published up to March 2026. Only articles that debated biological aspects were considered.
Results: The research yielded 105 articles, and cross-references, similar articles, and citing articles were analysed.
Conclusions: The review clarified the roles of the different components of the LR-PRP. A high concentration of platelets and mononuclear cells is desirable for tissue repair and regeneration. However, a possible healing role of granulocytes has emerged, while the presence of damaged erythrocytes must not be underestimated.
References
1. Kingsley CS. Blood coagulation; evidence of an antagonist to factor VI in platelet-rich human plasma. Nature. 1954; 173(4407):723-724.
2. Collins T, Alexander D, Barkatali B. Platelet-rich plasma: a narrative review. EFORT Open Rev. 2021; 6(4):225-235.
3. Mościcka P, Przylipiak A. History of autologous platelet-rich plasma: a short review. J Cosmet Dermatol. 2021; 20(9):2712-2714.
4. Khan FA, Parayaruthottam P, Roshan G, Menon V, Fidha M, Fernandes AK. Platelets and their pathways in dentistry: systematic review. J Int Soc Prev Community Dent. 2017; 7(Suppl 2):S55-S60.
5. Tözüm TF, Demiralp B. Platelet-rich plasma: a promising innovation in dentistry. J Can Dent Assoc. 2003; 69(10):664.
6. Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999; 14(4):529-535.
7. Trowbridge CC, Stammers AH, Woods E, Yen BR, Klayman M, Gilbert C. Use of platelet gel and its effects on infection in cardiac surgery. J Extra Corpor Technol. 2005; 37(4):381-386.
8. Englert SJ, Estep TH, Ellis-Stoll CC. Autologous platelet gel applications during cardiovascular surgery: effect on wound healing. J Extra Corpor Technol. 2005; 37(2):148-152.
9. Ferrari M, Zia S, Valbonesi M, et al. A new technique for hemodilution, preparation of autologous platelet-rich plasma and intraoperative blood salvage in cardiac surgery. Int J Artif Organs. 1987; 10(1):47-50.
10. Li S, Yang G, Zhang H, Li X, Lu Y. A systematic review on the efficacy of different types of platelet-rich plasma in the management of lateral epicondylitis. J Shoulder Elbow Surg. 2022; 31(7):1533-1544.
11. Anitua E, Sanchez M, Nurden AT, et al. Autologous fibrin matrices: a potential source of biological mediators that modulate tendon cell activities. J Biomed Mater Res A. 2006; 77(2):285-293.
12. Wu PIK, Diaz R, Borg-Stein J. Platelet-Rich Plasma. Phys Med Rehabil Clin N Am. 2016; 27(4):825-853.
13. Cieslik-Bielecka A, Choukroun J, Odin G, Dohan Ehrenfest DM. L-PRP/L-PRF in esthetic plastic surgery, regenerative medicine of the skin and chronic wounds. Curr Pharm Biotechnol. 2012; 13(7):1266-1277.
14. Kelm RC, Ibrahim O. Utility of platelet-rich plasma in aesthetics. Clin Dermatol. 2022; 40(1):19-28.
15. Asubiaro J, Avajah F. Platelet-rich plasma in aesthetic dermatology: current evidence and future directions. Cureus. 2024; 16(8):e66734.
16. Nanda S, Chauhan K, Shetty V, Dashore S, Bhatia S. Platelet-rich plasma in aesthetics. Indian Dermatol Online J. 2021; 12(Suppl 1):S41-S54.
17. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009; 27(3):158-167.
18. Dhurat R, Sukesh M. Principles and methods of preparation of platelet-rich plasma: a review and author’s perspective. J Cutan Aesthet Surg. 2014; 7(4):189-197.
19. Dohan Ehrenfest DM, Bielecki T, Mishra A, et al. In search of a consensus terminology in the field of platelet concentrates for surgical use: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), fibrin gel polymerization and leukocytes. Curr Pharm Biotechnol. 2012; 13(7):1131-1137.
20. Rossi LA, Murray IR, Chu CR, Muschler GF, Rodeo SA, Piuzzi NS. Classification systems for platelet-rich plasma. Bone Joint J. 2019; 101-B(8):891-896.
21. Mautner K, Malanga GA, Smith J, et al. A call for a standard classification system for future biologic research: the rationale for new PRP nomenclature. PM R. 2015; 7(4 Suppl):S53-S59.
22. Rubio-Azpeitia E, Bilbao AM, Sánchez P, Delgado D, Andia I. The properties of 3 different plasma formulations and their effects on tendinopathic cells. Am J Sports Med. 2016; 44(8):1952-1961.
23. Yin W, Qi X, Zhang Y, et al. Advantages of pure platelet-rich plasma compared with leukocyte- and platelet-rich plasma in promoting repair of bone defects. J Transl Med. 2016; 14:73.
24. Yin WJ, Xu HT, Sheng JG, et al. Advantages of Pure Platelet-Rich Plasma compared with leukocyte- and platelet-rich plasma in treating rabbit knee osteoarthritis. Med Sci Monit. 2016; 22:1280-1290.
25. Zhang L, Chen S, Chang P, et al. Harmful effects of leukocyte-rich platelet-rich plasma on rabbit tendon stem cells in vitro. Am J Sports Med. 2016; 44(8):1941-1951.
26. Zhou Y, Zhang J, Wu H, Hogan MV, Wang JHC. The differential effects of leukocyte-containing and pure platelet-rich plasma (PRP) on tendon stem/progenitor cells - implications of PRP application for the clinical treatment of tendon injuries. Stem Cell Res Ther. 2015; 6(1):173.
27. Araya N, Miyatake K, Tsuji K, et al. Intra-articular injection of pure platelet-rich plasma is the most effective treatment for joint pain by modulating synovial inflammation and calcitonin gene-related peptide expression in a rat arthritis model. Am J Sports Med. 2020; 48(8):2004-2012.
28. Abbas A, Du JT, Dhotar HS. The effect of leukocyte concentration on platelet-rich plasma injections for knee osteoarthritis: a network meta-analysis. J Bone Joint Surg Am. 2022; 104(6):559-570.
29. Zhang B, Dong B, Wang L, et al. Comparison of the efficacy of autologous Lp-PRP and Lr-PRP for treating intervertebral disc degeneration: in vitro and in vivo study. J Orthop Surg Res. 2024; 19(1):731.
30. Miura T, Yeow BEB, Jujo Y, et al. Comparison of the effects of leukocyte-rich and leukocyte-poor platelet-rich plasma following bone marrow stimulation technique on osteochondral lesions of the talus in athletes: a retrospective cohort study. Int Orthop. 2026; 50(2):401-410.
31. Braun HJ, Kim HJ, Chu CR, Dragoo JL. The effect of platelet-rich plasma formulations and blood products on human synoviocytes: implications for intra-articular injury and therapy. Am J Sports Med. 2014; 42(5):1204-1210.
32. Yan R, Gu Y, Ran J, et al. Intratendon delivery of leukocyte-poor platelet-rich plasma improves healing compared with leukocyte-rich platelet-rich plasma in a rabbit achilles tendinopathy model. Am J Sports Med. 2017; 45(8):1909-1920.
33. Chen L, Jin S, Yao Y, He S, He J. Comparison of clinical efficiency between intra-articular injection of platelet-rich plasma and hyaluronic acid for osteoarthritis: a meta-analysis of randomized controlled trials. Ther Adv Musculoskelet Dis. 2023; 15:1759720X231157043.
34. Li XH, Zhou X, Zeng S, et al. Effects of intramyocardial injection of platelet-rich plasma on the healing process after myocardial infarction. Coron Artery Dis. 2008; 19(5):363-370.
35. Muthu S, Patel S, Selvaraj P, Jeyaraman M. Comparative analysis of leucocyte poor vs leucocyte rich platelet-rich plasma in the management of lateral epicondylitis: systematic review & meta-analysis of randomised controlled trials. J Clin Orthop Trauma. 2021; 19:96-107.
36. Di Martino A, Boffa A, Andriolo L, et al. Leukocyte-rich versus leukocyte-poor platelet-rich plasma for the treatment of knee osteoarthritis: a double-blind randomized trial. Am J Sports Med. 2022; 50(3):609-617.
37. Martín-Vega M, Gómez-Carrión Á, Zaragoza-García I, et al. Leukocyte-rich versus leukocyte-poor platelet-rich plasma for osteoarthritis: a systematic review. Regen Ther. 2026; 31:101078.
38. Hanisch K, Wedderkopp N. Platelet-rich plasma (PRP) treatment of noninsertional Achilles tendinopathy in a two case series: no significant difference in effect between leukocyte-rich and leukocyte-poor PRP. Orthop Res Rev. 2019; 11:55-60.
39. Cavallo C, Filardo G, Mariani E, et al. Comparison of platelet-rich plasma formulations for cartilage healing: an in vitro study. J Bone Joint Surg Am. 2014; 96(5):423-429.
40. Ziegler CG, Van Sloun R, Gonzalez S, et al. Characterization of growth factors, cytokines, and chemokines in bone marrow concentrate and platelet-rich plasma: a prospective analysis. Am J Sports Med. 2019; 47(9):2174-2187.
41. Shim JW, Lee JS, Park YB, Cho HC, Jung HS. The effect of leucocyte concentration of platelet-rich plasma on outcomes in patients with lateral epicondylitis: a systematic review and meta-analysis. J Shoulder Elbow Surg. 2022; 31(3):634-645.
42. Lin KY, Chen P, Chen ACY, Chan YS, Lei KF, Chiu CH. Leukocyte-rich platelet-rich plasma has better stimulating effects on tenocyte proliferation compared with leukocyte-poor platelet-rich plasma. Orthop J Sports Med. 2022; 10(3):23259671221084706.
43. Allison DJ, Loh E, Burnham R, Burnham T, Smith A. Leukocyte poor platelet rich plasma vs leukocyte rich platelet rich plasma as a treatment for cervical facetogenic pain: a pooled analysis. Interv Pain Med. 2025; 4(1):100566.
44. Lin LP, Pang JHS, Yu TY, Hsu CC, Liao YC, Tsai WC. Leukocyte-rich platelet-rich plasma is superior to leukocyte-poor platelet-rich plasma in improving muscle healing by promoting angiogenesis. J Orthop Res. 2025; 43(9):1545-1555.
45. Jiang G, Wu Y, Meng J, et al. Comparison of leukocyte-rich platelet-rich plasma and leukocyte-poor platelet-rich plasma on Achilles tendinopathy at an early stage in a rabbit model. Am J Sports Med. 2020; 48(5):1189-1199.
46. Yaradilmis YU, Demirkale I, Safa Tagral A, Caner Okkaoglu M, Ates A, Altay M. Comparison of two platelet rich plasma formulations with viscosupplementation in treatment of moderate grade gonarthrosis: a prospective randomized controlled study. J Orthop. 2020; 20:240-246.
47. Yu D, Zhao J, Zhao K. The efficacy of platelet-rich plasma preparation protocols in the treatment of osteoarthritis: a network meta-analysis of randomized controlled trials. J Orthop Surg Res. 2025; 20(1):614.
48. Peng Y, Wu W, Li X, et al. Effects of leukocyte-rich platelet-rich plasma and leukocyte-poor platelet-rich plasma on the healing of bone-tendon interface of rotator cuff in a mice model. Platelets. 2022; 33(7):1075-1082.
49. Williams M. What are platelets and why are they important? Published online 2026. Accessed April 7, 2026. https://www.hopkinsmedicine.org/health/conditions-and-diseases/what-are-platelets-and-why-are-they-important
50. Mazzucco L, Balbo V, Cattana E, Guaschino R, Borzini P. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, RegenPRP-Kit, Plateltex and one manual procedure. Vox Sang. 2009; 97(2):110-118.
51. Giusti I, Rughetti A, D’Ascenzo S, et al. Identification of an optimal concentration of platelet gel for promoting angiogenesis in human endothelial cells. Transfusion. 2009; 49(4):771-778.
52. Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001; 10(4):225-228.
53. Bansal H, Leon J, Pont JL, et al. Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: correct dose critical for long term clinical efficacy. Sci Rep. 2021; 11(1):3971.
54. Weibrich G, Hansen T, Kleis W, Buch R, Hitzler WE. Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. Bone. 2004; 34(4):665-671.
55. Graziani F, Ivanovski S, Cei S, Ducci F, Tonetti M, Gabriele M. The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. Clin Oral Implants Res. 2006; 17(2):212-219.
56. Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: a review. Curr Rev Musculoskelet Med. 2008; 1(3-4):165-174.
57. Oudelaar BW, Peerbooms JC, Huis In ’t Veld R, Vochteloo AJH. Concentrations of blood components in commercial platelet-rich plasma separation systems: a review of the literature. Am J Sports Med. 2019; 47(2):479-487.
58. Castillo TN, Pouliot MA, Kim HJ, Dragoo JL. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med. 2011; 39(2):266-271.
59. Russell RP, Apostolakos J, Hirose T, Cote MP, Mazzocca AD. Variability of platelet-rich plasma preparations. Sports Med Arthrosc Rev. 2013; 21(4):186-190.
60. Moojen DJF, Everts PAM, Schure RM, et al. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res. 2008; 26(3):404-410.
61. Davis VL, Abukabda AB, Radio NM, et al. Platelet-rich preparations to improve healing. Part II: platelet activation and enrichment, leukocyte inclusion, and other selection criteria. J Oral Implantol. 2014; 40(4):511-521.
62. Denapoli PMA, Stilhano RS, Ingham SJM, Han SW, Abdalla RJ. Platelet-rich plasma in a murine model: leukocytes, growth factors, Flt-1, and muscle healing. Am J Sports Med. 2016; 44(8):1962-1971.
63. Kobayashi Y, Saita Y, Nishio H, et al. Leukocyte concentration and composition in platelet-rich plasma (PRP) influences the growth factor and protease concentrations. J Orthop Sci. 2016; 21(5):683-689.
64. Zimmermann R, Jakubietz R, Jakubietz M, et al. Different preparation methods to obtain platelet components as a source of growth factors for local application. Transfusion. 2001; 41(10):1217-1224.
65. Anitua E, Zalduendo MM, Prado R, Alkhraisat MH, Orive G. Morphogen and proinflammatory cytokine release kinetics from PRGF-Endoret fibrin scaffolds: evaluation of the effect of leukocyte inclusion. J Biomed Mater Res A. 2015; 103(3):1011-1020.
66. Assirelli E, Filardo G, Mariani E, et al. Effect of two different preparations of platelet-rich plasma on synoviocytes. Knee Surg Sports Traumatol Arthrosc. 2015; 23(9):2690-2703.
67. Dragoo JL, Braun HJ, Durham JL, et al. Comparison of the acute inflammatory response of two commercial platelet-rich plasma systems in healthy rabbit tendons. Am J Sports Med. 2012; 40(6):1274-1281.
68. McCarrel TM, Minas T, Fortier LA. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am. 2012; 94(19):e143(1-8).
69. Mariani E, Canella V, Cattini L, et al. Leukocyte-rich platelet-rich plasma injections do not up-modulate intra-articular pro-inflammatory cytokines in the osteoarthritic knee. PLoS One. 2016; 11(6):e0156137.
70. Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med. 2011; 39(10):2135-2140.
71. Marathe A, Patel SJ, Song B, et al. Double-spin leukocyte-rich platelet-rich plasma is predominantly lymphocyte rich with notable concentrations of other white blood cell subtypes. Arthrosc Sports Med Rehabil. 2022; 4(2):e335-e341.
72. Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. Int J Mol Sci. 2020; 21(20):7794.
73. Turajane T, Cheeva-Akrapan V, Saengsirinavin P, Lappaiwong W. Composition of platelet-rich plasma prepared from knee osteoarthritic patients: platelets, leukocytes, and subtypes of leukocyte. Cureus. 2023; 15(3):e36399.
74. Baria M, Vasileff WK, Miller M, Borchers J, Flanigan DC, Durgam SS. Cellular components and growth factor content of platelet-rich plasma with a customizable commercial system. Am J Sports Med. 2019; 47(5):1216-1222.
75. Harrison TE, Bowler J, Levins TN, Reeves KD, Cheng AL. Platelet-Rich Plasma centrifugation changes leukocyte ratios. Cureus. 2021; 13(4):e14470.
76. Ogle ME, Segar CE, Sridhar S, Botchwey EA. Monocytes and macrophages in tissue repair: implications for immunoregenerative biomaterial design. Exp Biol Med (Maywood). 2016; 241(10):1084-1097.
77. Italiani P, Mazza EMC, Lucchesi D, et al. Transcriptomic profiling of the development of the inflammatory response in human monocytes in vitro. PLoS One. 2014; 9(2):e87680.
78. Gieseck RL, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol. 2018; 18(1):62-76.
79. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008; 8(12):958-969.
80. Lana JF, Huber SC, Purita J, et al. Leukocyte-rich PRP versus leukocyte-poor PRP - The role of monocyte/macrophage function in the healing cascade. J Clin Orthop Trauma. 2019; 10(Suppl 1):S7-S12.
81. Ferrante CJ, Leibovich SJ. Regulation of macrophage polarization and wound healing. Adv Wound Care (New Rochelle). 2012; 1(1):10-16.
82. Lee SJ, Yoon BR, Kim HY, Yoo SJ, Kang SW, Lee WW. Activated platelets convert CD14+CD16- into CD14+CD16+ monocytes with enhanced FcγR-mediated phagocytosis and skewed M2 polarization. Front Immunol. 2020; 11:611133.
83. Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. 2016; 44(3):450-462.
84. Das A, Sinha M, Datta S, et al. Monocyte and macrophage plasticity in tissue repair and regeneration. Am J Pathol. 2015; 185(10):2596-2606.
85. Reinke JM, Sorg H. Wound repair and regeneration. Eur Surg Res. 2012; 49(1):35-43.
86. Pesce JT, Ramalingam TR, Mentink-Kane MM, et al. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog. 2009; 5(4):e1000371.
87. Ubezio G, Ghio M, Contini P, et al. Bio-modulators in platelet-rich plasma: a comparison of the amounts in products from healthy donors and patients produced with three different techniques. Blood Transfus. 2014; 12 Suppl 1(Suppl 1):s214-220.
88. Weirather J, Hofmann UDW, Beyersdorf N, et al. Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circ Res. 2014; 115(1):55-67.
89. Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJC, John S, Taams LS. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci U S A. 2007; 104(49):19446-19451.
90. Italiani P, Boraschi D. From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front Immunol. 2014; 5:514.
91. Boswell SG, Cole BJ, Sundman EA, Karas V, Fortier LA. Platelet-rich plasma: a milieu of bioactive factors. Arthroscopy. 2012; 28(3):429-439.
92. Jacobsen EA, Helmers RA, Lee JJ, Lee NA. The expanding role(s) of eosinophils in health and disease. Blood. 2012; 120(19):3882-3890.
93. Marone G, Varricchi G, Loffredo S, Granata F. Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis. Eur J Pharmacol. 2016; 778:146-151.
94. Tiligada E, Levi-Schaffer F. Infiltrating basophils tune injured skin barrier recovery. J Invest Dermatol. 2024; 144(8):1673-1675.
95. Zhang Y, Peng X, Ren K, et al. Sensitizer-induced basophils accelerate skin re-epithelialization via IL-4/IL-13-mediated macrophage polarization. Allergy. 2026; 81(5):1487-1499.
96. Bex J, Peter V, Saji C, et al. Basophils drive the resolution and promote wound healing in adult and aged mice. J Exp Med. 2026; 223(5):e20240764.
97. Fedorova NV, Ksenofontov AL, Serebryakova MV, et al. Neutrophils release metalloproteinases during adhesion in the presence of insulin, but cathepsin G in the presence of glucagon. Mediators Inflamm. 2018; 2018:1574928.
98. Zhou Y, Wang JHC. PRP treatment efficacy for tendinopathy: a review of basic science studies. Biomed Res Int. 2016; 2016:9103792.
99. Kovtun A, Bergdolt S, Wiegner R, Radermacher P, Huber-Lang M, Ignatius A. The crucial role of neutrophil granulocytes in bone fracture healing. Eur Cell Mater. 2016; 32:152-162.
100. Phillipson M, Kubes P. The healing power of neutrophils. Trends Immunol. 2019; 40(7):635-647.
101. Toumi H, F’guyer S, Best TM. The role of neutrophils in injury and repair following muscle stretch. J Anat. 2006; 208(4):459-470.
102. Meirer K, Steinhilber D, Proschak E. Inhibitors of the arachidonic acid cascade: interfering with multiple pathways. Basic Clin Pharmacol Toxicol. 2014; 114(1):83-91.
103. Parrish W. Physiology of blood components in wound healing: an appreciation of cellular co-operativity in Platelet Rich Plasma action. J Exerc Sports Orthop. 2017; 4(2):1-14.
104. Page C, Pitchford S. Neutrophil and platelet complexes and their relevance to neutrophil recruitment and activation. Int Immunopharmacol. 2013; 17(4):1176-1184.
105. Marwick JA, Mills R, Kay O, et al. Neutrophils induce macrophage anti-inflammatory reprogramming by suppressing NF-κB activation. Cell Death Dis. 2018; 9(6):665.
106. Tajima T, Sekimoto T, Yamaguchi N, et al. Hemoglobin stimulates the expression of ADAMTS-5 and ADAMTS-9 by synovial cells: a possible cause of articular cartilage damage after intra-articular hemorrhage. BMC Musculoskelet Disord. 2017; 18(1):449.
107. Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercellotti GM. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood. 2013; 121(8):1276-1284.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Sheila Veronese, Andrea Sbarbati
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
